Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity
Authors:
- 1 September 2004
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 5 (6) , 643-655
Abstract
The application of a pharmacogenetic approach to antiretroviral drug therapy represents a significant challenge, as treatment involves multiple drugs and drug classes with the potential for significant variability in drug-host, as well as drug-drug, interactions. However, despite this inherent complexity, considerable gains have been made in understanding how genetic factors influence the efficacy and toxicity of HIV therapy. In this review the available evidence regarding genetic variation in drug disposition will be examined, including the potential for relatively polymorphic drug-metabolizing enzymes (e.g., cytochrome P450 isoforms) and drug transporters (e.g., P-glycoprotein) to influence the disposition of HIV protease inhibitor and non-nucleoside reverse transcriptase inhibitor drugs. In addition, the role of genetic variation in determining the immune response to drug-specific antigens will be considered as a potentially significant determinant of susceptibility to idiosyncratic drug reactions (e.g., major histocompatibility complex alleles associated with abacavir hypersensitivity). The current and potential clinical utility of pharmacogenetic testing in HIV management will also be emphasized.Keywords
This publication has 74 references indexed in Scilit:
- Transporters and Renal Drug EliminationAnnual Review of Pharmacology and Toxicology, 2004
- Effects of Purifying and Adaptive Selection on Regional Variation in Human mtDNAScience, 2004
- Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophyAIDS, 2003
- TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophyAIDS, 2002
- DelavirdineClinical Pharmacokinetics, 2001
- Fine Localization of a Major Disease-Susceptibility Locus for Diffuse PanbronchiolitisThe American Journal of Human Genetics, 2000
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.Journal of Clinical Investigation, 1998
- Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with RitonavirThe Journal of Clinical Pharmacology, 1998